Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
ACT-539313
Другие языки:

    ACT-539313

    Подписчиков: 0, рейтинг: 0
    ACT-539313
    ACT-539313 structure.png
    Clinical data
    Routes of
    administration    		 Oral
    Drug class Orexin receptor antagonist
    Pharmacokinetic data
    Elimination half-life 3.3–6.5 hours
    Identifiers
    • 4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(R)-3-(3-[1,2,3]triazol-2-yl-benzyl)morpholin-4-yl]methanone
    CAS Number
    PubChem CID
    UNII
    Chemical and physical data
    Formula C23H23N7O2
    Molar mass 429.484 g·mol−1
    3D model (JSmol)
    • CC1=CC(=C(C=C1)C(=O)N2CCOC[C@H]2CC3=CC(=CC=C3)N4N=CC=N4)N5N=CC=N5
    • InChI=1S/C23H23N7O2/c1-17-5-6-21(22(13-17)30-26-9-10-27-30)23(31)28-11-12-32-16-20(28)15-18-3-2-4-19(14-18)29-24-7-8-25-29/h2-10,13-14,20H,11-12,15-16H2,1H3/t20-/m1/s1
    • Key:GKPHAIOJCHBZCT-HXUWFJFHSA-N

    ACT-539313 is an orexin antagonist medication which is under development for the treatment of binge eating disorder and was previously under development for the treatment of anxiety disorders. It is an orally active small-molecule compound with an elimination half-life of 3.3 to 6.5 hours and acts as a selective orexin OX1 receptor antagonist (1-SORA). As of May 2022, the drug is in phase 2 clinical trials for binge eating disorder. Following negative efficacy results of a phase 2 trial of ACT-539313 for binge eating disorder, Idorsia (the developer of ACT-539313) signaled in May 2022 that it would not pursue further development of the drug for this indication.


    Новое сообщение